{
    "clinical_study": {
        "@rank": "149743", 
        "arm_group": [
            {
                "arm_group_label": "Ketorolac tromethamine (SPRIX)", 
                "arm_group_type": "Other", 
                "description": "A SPRIX dose will be one 15.75 mg spray in each nostril for a total dose of 31.5 mg which can be repeated every 6-8 hrs as needed for post vasectomy pain with a maximum daily dose of 126 mg to be continued for up to 5 days."
            }, 
            {
                "arm_group_label": "Standard of care", 
                "arm_group_type": "Other", 
                "description": "The intervention used will be standard of care"
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate the efficacy, tolerability and safety of intranasal ketorolac tromethamine\n      (SPRIX) as an option for pain management in post vasectomy patients."
        }, 
        "brief_title": "Intranasal Ketorolac Tromethamine (SPRIX) as a Short Term Pain Management of Post-Vasectomy Pain", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Post Vasectomy Pain", 
        "eligibility": {
            "criteria": {
                "textblock": "INCLUSION CRITERIA\n\n          1. Male Subject must be between the age twenty five (25) years and sixty four (64)\n\n          2. Willing and able to provide an informed consent\n\n          3. Has made decision to undergo vasectomy\n\n          4. Subject is in good general physical condition as assessed by the Principal\n             Investigator\n\n        EXCLUSION CRITERIA\n\n          1. Current treatment with or known allergy or sensitivity to  all forms of ketorolac\n             tromethamine , aspirin , other non steroidal anti inflammatory drugs (NSAIDs) or\n             Ethylenediaminetetraacetic acid (EDTA)\n\n          2. Use of narcotics/opiate or medical marijuana within one (1) week prior  to the\n             baseline visit and entire study participation\n\n          3. Use of illegal drugs by self reporting\n\n          4. History of drug or alcohol abuse within five (5) years of screening visit\n\n          5. History of suicide attempt within five (5) years of screening visit\n\n          6. A  diagnosis of a severe neuro-psychiatric disease\n\n          7. Subject who is currently receiving investigational  drug(s) or participated in a\n             clinical trial involving investigational drug(s) within thirty (30) day of the\n             screening visit\n\n          8. Subject with history of any of the following coronary conditions: (chronic stable\n             angina being currently treated with long acting nitrates, chronic stable angina\n             require treatment with short acting nitrates with 90 days of visit 1, angina\n             occurring during sexual intercourse in the last six months, unstable angina within\n             six months of visit 1\n\n          9. Resting, sitting blood pressure (BP) > 160mm Hg in systolic pressure or > 100mm Hg is\n             diastolic pressure at screening.  If a patient is found to have untreated significant\n             hypertension at screening and antihypertensive treatment is initiated, assessment for\n             study eligibility should be deferred until BP and antihypertensive medication have\n             been stable for at least one month.  For patients with previously diagnosed\n             hypertension, antihypertensive medications must be stable for at least one month\n             prior to screening.\n\n         10. Known or suspected cerebrovascular bleeding, hemorrhagic diathesis or incomplete\n             hemostasis, and those at high risk of bleeding, have history of a bleeding problem or\n             low platelet count or coagulation disorder or are on therapy that affects homeostasis\n\n         11. Active peptic ulcer disease, recent GI bleeding or perforation, or a history of\n             peptic ulcers or GI bleeding\n\n         12. History of asthma, urticaria or other allergic-type reaction after taking aspirin or\n             other non steroidal inflammatory drugs (NASIDs)\n\n         13. Subject over sixty four (64) years of age\n\n         14. Subject with any clinically significant renal function or liver abnormality\n\n         15. Subject who has history of swelling of face, mouth, tongue, lips, gums, neck, or\n             throat (angioedema) or with cardiac decompensation or similar conditions\n\n         16. Major surgery scheduled within 3 weeks or screening and for entire participation of\n             study\n\n         17. Current exfoliative dermatitis, Stevens-Johnson syndrome or toxic epidermal\n             necrolysis\n\n         18. Any condition in the opinion of the investigator that makes the subject unsuitable\n             for study\n\n             -"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "64 Years", 
            "minimum_age": "25 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02000388", 
            "org_study_id": "1012-2011-SPRIX"
        }, 
        "intervention": [
            {
                "arm_group_label": "Ketorolac tromethamine (SPRIX)", 
                "intervention_name": "Ketorolac Tromethamine", 
                "intervention_type": "Drug", 
                "other_name": "SPRIX"
            }, 
            {
                "arm_group_label": "Standard of care", 
                "intervention_name": "Standard of Care", 
                "intervention_type": "Other", 
                "other_name": "Standard of Care"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Ketorolac Tromethamine", 
                "Ketorolac"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "December 3, 2013", 
        "number_of_arms": "2", 
        "official_title": "Efficacy and Safety of Intranasal Ketorolac Tromethamine (SPRIX) as a Short Term Pain Management Tool for Adult Male Patients With Post-Vasectomy Pain", 
        "overall_official": {
            "affiliation": "Citrus Valley Medical Research, Inc.", 
            "last_name": "Edward L Davis, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Pain Scores on the Visual Analog Scale", 
            "safety_issue": "No", 
            "time_frame": "5 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02000388"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "To determine Number of Participants with Adverse Events as a Measure of Safety and Tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "5 Days"
        }, 
        "source": "Citrus Valley Medical Research, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Citrus Valley Medical Research, Inc.", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}